Showing results (1-10 of 26) with videos related to
Sort By:
Pageof 3
Expert Review of Pharmacoeconomics & Outcomes Research|September 2, 2015
Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis CVicente Gimeno-Ballester, Javier Mar, Ramón San MiguelPharmacoeconomics|September 4, 2013
Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patientsAntonio Blázquez-Pérez, Ramón San Miguel, Javier MarExpert Review of Pharmacoeconomics & Outcomes Research|April 25, 2014
Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literatureRamón San Miguel, Vicente Gimeno-Ballester, Javier MarGut|October 15, 2014
Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis CRamón San Miguel, Vicente Gimeno-Ballester, Antonio Blázquez, et al.Medicina Clinica|December 15, 2015
[Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis]Javier Mar, Lorea Mar-Barrutia, Vicente Gimeno-Ballester, et al.International Journal of Clinical Pharmacy|September 26, 2012
Potential for simplification of HIV treatment with boosted protease inhibitor monotherapyElena Reina, Ramón San Miguel, Natalia Larrea, et al.Expert Review of Gastroenterology & Hepatology|August 9, 2016
Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patientsVicente Gimeno-Ballester, Javier Mar, Aisling O'Leary, et al.Expert Review of Gastroenterology & Hepatology|September 15, 2016
Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidenceVicente Gimeno-Ballester, Miguel Ángel Simón, Cristina Trigo, et al.Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 23, 2019
Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general populationRegina Juanbeltz, Jesús Castilla, Iván Martínez-Baz, et al.Pharmacy World & Science : PWS|August 28, 2007
Measuring health-related quality of life in drug clinical trials: is it given due importance?Ramón San Miguel, Ana María López-González, Eduardo Sanchez-Iriso, et al.Pageof 3